Is Bristol-Myers Stock Outperforming the Dow?

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, and markets biopharmaceutical products. Valued at a market cap of $121.4 billion, the company offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas.

Companies valued at $10 billion or more are typically classified as “large-cap stocks,” and BMY fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the drug manufacturers – general industry. The company’s strengths stem from its strong R&D pipeline, high-performing drugs like OPDIVO and Eliquis, and strategic acquisitions that expand its portfolio. BMY leverages solid patent protection, a global presence, and expertise in biologics and cell therapy to drive sustained growth and innovation.